Pharmacokinetics of Remifentanil in Anesthetized Pediatric Patients Undergoing Elective Surgery or Diagnostic Procedures
- 1 December 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 93 (6) , 1393-1401
- https://doi.org/10.1097/00000539-200112000-00008
Abstract
Remifentanil hydrochloride is an ultra-short-acting opioid that undergoes rapid metabolism by tissue and plasma esterases. We aimed to characterize the pharmacokinetics and determine the hemodynamic profile of remifentanil after a single-bolus dose in children aged 0 to 18 yr. Forty-two children undergoing elective surgical procedures received remifentanil 5 μg/kg infused over 1 min. Patients were divided into age groups as follows: young infants (≤2 mo), older infants (>2 mo to <2 yr), young children (2 to <7 yr), older children (7 to <13 yr), adolescents (13 to <16 yr), and young adults (16 to <18 yr). Arterial blood samples were collected and analyzed by mass spectroscopy to determine remifentanil pharmacokinetic profiles. Hemodynamic measurements for remifentanil’s effect were made after the infusion. Methods of statistical analysis included analysis of variance and linear regression, with significance at P ≤ 0.05. Complete remifentanil pharmacokinetic data were obtained from 34 patients. The volume of distribution was largest in the infants <2 mo (mean, 452 mL/kg) and decreased to means of 223 to 308 mL/kg in the older patients. There was a more rapid clearance in the infants <2 mo of age (90 mL · kg−1 · min−1) and infants 2 mo to 2 yr (92 mL · kg−1 · min−1) than in the other groups (means, 46 to 76 mL · kg−1 · min−1). The half-life was similar in all age groups, with means of 3.4 to 5.7 min. Seven subjects (17%) developed hypotension related to the remifentanil bolus. Remifentanil showed an extremely rapid elimination similar to that in adults. The fast clearance rates observed in neonates and infants, as well as the lack of age-related changes in half-life, are in sharp contrast to the pharmacokinetic profile of other opioids. Remifentanil in a bolus dose of 5 μg/kg may cause hypotension in anesthetized children.Keywords
This publication has 23 references indexed in Scilit:
- The Effects of Cardiopulmonary Bypass on Remifentanil Kinetics in Children Undergoing Atrial Septal Defect RepairAnesthesia & Analgesia, 1999
- Clearance of Morphine in Postoperative Infants During Intravenous InfusionAnesthesia & Analgesia, 1998
- Pharmacokinetics Anesthesiologists, and Pharmacodynamics of Remifentanil in Persons with Renal Failure Compared with Healthy VolunteersAnesthesiology, 1997
- A Randomized Multicenter Study of Remifentanil Compared with Alfentanil, Isoflurane, or Propofol in Anesthetized Pediatric Patients Undergoing Elective Strabismus SurgeryAnesthesia & Analgesia, 1997
- Quantification of GR90291 in human blood by high resolution gas chromatography—mass selective detection (HRGC-MSD)Journal of Pharmaceutical and Biomedical Analysis, 1994
- Determination of remifentanil in human blood by liquid-liquid extraction and capillary GC-HRMS-SIM using a deuterated internal standardJournal of Pharmaceutical and Biomedical Analysis, 1994
- Pharmacokinetics of Remifentanil (GI87084B) and Its Major Metabolite (GI90291) in Patients Undergoing Elective Inpatient SurgeryAnesthesiology, 1993
- The Pharmacokinetics of the New Short-acting Opioid Remifentanil (GI87084B) in Healthy Adult Male VolunteersAnesthesiology, 1993
- Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgesicsJournal of Medicinal Chemistry, 1991
- The Pharmacokinetics of Alfentanil in ChildrenAnesthesiology, 1987